http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2097106-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bfb4118012a5d07c81b8bf80da3e1fed |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2007-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a422226da55ebc258ceda286a886aa5 |
| publicationDate | 2009-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2097106-A2 |
| titleOfInvention | Novel uses and methods |
| abstract | The present invention relates to a novel use of alpha10, or a heterodimer thereof, for affecting cartilage ECM turnover. Further, it relates to the use of a binding entity binding specifically to alpha10 or a heterodimer thereof in the preparation of a medicament for treating a condition affecting ECM, such as RA and OA. In particular, the invention relates to a method of treating an individual with a condition affecting ECM turnover, comprising administering to the individual an effective amount of a binding agent entity binding specifically to alpha10, or a heterodimer thereof. |
| priorityDate | 2006-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 612.